evolv. resolv. ZUBSOLV®.  It’s time for a change.


Is it time to take a different path on your road to recovery?

ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) is a prescription medicine used to treat adults who are addicted to opioid drugs (either prescription or illegal) as part of a complete treatment program that also includes counseling and behavioral therapy. Call (855) 982-7658 for more information on Zubsolv.

The results are in and patients prefer ZUBSOLV® attributes to Suboxone® film.1

More than 70% of patients preferred ZUBSOLV attributes such as taste, mouthfeel, and ease of administration when compared to Suboxone film.

70%

Overall Preference

72%

Ease of Administration

ZUBSOLV® had comparable number of patients remaining in the study at Day 15 vs Suboxone® film (74.9% vs 74.4%)1


ZUBSOLV showed comparable retention at Day 15 vs Suboxone film

ZUBSOLV
0%
Suboxone film
0%

Withdrawal Symptoms (SOWS)1

ZUBSOLV
0 %
Suboxone film
0 %

SOWS = Subjective Opiate Withdrawal Scale. SOWS is measured on a scale of 0-64 where a lower score is favorable. Note: Numbers are due to rounding.

Opioid Cravings (VAS)1

ZUBSOLV
0 %
Suboxone film
0 %

VAS = Visual Analog Scale.  VAS is measured on a scale of 0-100 where a lower score is favorable. Note: Numbers are due to rounding.


Adverse events were similar across treatments. See the full study results.

Adverse events were similar across treatments1

Treatment-related, treatment-emergent adverse events (TEAEs) in ≥2% of patients Day 3 through Day 15 by system organ class (safety population)


System Organ Class

  • Patients with any TEAEs
  • Gastrointestinal disorders
  • Constipation
  • Nervous system disorder
  • Headache

ZUBSOLV

  • 42 (11.8%)
  • 22 (6.2%)
  • 10 (2.8%)
  • 12 (3.4%)
  • 5 (1.4%)

Suboxone film

  • 37 (10.8%)
  • 18 (5.2%)
  • 12 (3.5%)
  • 12 (3.5%)
  • 7 (2.0%)

The percentages of patients with treatment-related TEAEs were similar between the 2 treatments (post Day 3 through Day 15, 11.8% versus 10.8% for ZUBSOLV and Suboxone film, respectively)

  • Gastrointestinal effects were minimal with constipation reported in <5% of patients in the study. Similar improvements were demonstrated in constipation symptoms from baseline to Day 15 in both groups.
  • Nervous system disorders were similar between groups, all were mild to moderate in severity with headache being the most commonly reported event

97% of treatment-related TEAEs were of mild or moderate severity

No deaths occurred during the study

1. Data on file. Orexo US, Inc.

Ask your doctor about ZUBSOLV!


IMPORTANT SAFETY INFORMATION

Indication

ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) is a prescription medicine used to treat adults who are addicted to opioid drugs (either prescription or illegal) as part of a complete treatment program that also includes counseling and behavioral therapy.

Important Safety Information

  • Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a medical emergency and can result in death. Get emergency help right away.

  • ZUBSOLV can cause serious and life-threatening breathing problems. Call your doctor right away or get emergency help if (a) you feel faint, dizzy, or confused; (b) your breathing gets much slower than is normal for you; (c) you feel sleepy and uncoordinated; (d) you have blurred vision; (e) you have slurred speech; (f) you cannot think well or clearly; or (g) you have slowed reflexes and breathing. In an emergency, have family members tell the emergency department staff that you are physically dependent on an opioid and are being treated with ZUBSOLV.

  • The most common side effects of ZUBSOLV include: headache, drug withdrawal syndrome, nausea, decrease in sleep (insomnia), vomiting, pain, increased sweating, swelling of the extremities, and constipation. Tell your doctor about any side effect that bothers you or that does not go away.

  • Your doctor may monitor liver function before and during treatment with ZUBSOLV.

  • ZUBSOLV is not recommended for initiation of treatment in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal. However, ZUBSOLV may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone.

  • Do not switch from ZUBSOLV to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of ZUBSOLV is not the same as the amount of buprenorphine in other medicines that contain buprenorphine. Your doctor will prescribe a starting dose of buprenorphine that may be different than other buprenorphine-containing medicines you may have been taking.

  • ZUBSOLV contains an opioid that can cause physical dependence. Do not stop taking ZUBSOLV without talking to your doctor. You could become sick with uncomfortable withdrawal signs and symptoms because your body has become used to this medicine. Physical dependence is not the same as drug addiction.

  • ZUBSOLV is not for occasional or “as needed” use. An overdose, and even death, can happen if you take benzodiazepines, sedatives, tranquilizers, or alcohol while using ZUBSOLV. Ask your doctor what you should do if you are taking one of these. You should not drink alcohol while taking ZUBSOLV, as this can lead to loss of consciousness or even death.

  • Do not inject (“shoot-up”) ZUBSOLV. Injecting ZUBSOLV may cause life-threatening infections and other serious health problems. Injecting ZUBSOLV may cause serious withdrawal symptoms such as pain, cramps, vomiting, diarrhea, anxiety, sleep problems, and cravings.

  • Before taking ZUBSOLV, tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

  • Before taking ZUBSOLV, tell your doctor if you are pregnant or plan to become pregnant. It is not known if ZUBSOLV will harm your unborn baby. If you take ZUBSOLV while pregnant, your baby may have symptoms of withdrawal at birth. Talk to your doctor if you are pregnant or plan to become pregnant.

  • Before taking ZUBSOLV, tell your doctor if you are breastfeeding or plan to breastfeed Nursing mothers: Caution should be exercised when buprenorphine-containing products are administered to a nursing woman. Talk to your doctor about the best way to feed your baby if you take ZUBSOLV. Monitor your baby for increased sleepiness and breathing problems.

  • Do not drive, operate heavy machinery, or perform any other dangerous activities until you know how ZUBSOLV affects you. Buprenorphine can cause drowsiness and slow reaction times. This may happen more often in the first few weeks of treatment when your dose is being changed, but can also happen if you drink alcohol or take other sedative drugs when you take ZUBSOLV.

  • ZUBSOLV is a controlled substance (CIII) because it contains buprenorphine, which can be a target for people who abuse prescription medicines or street drugs. Keep your ZUBSOLV in a safe place to protect it from theft. Never give your ZUBSOLV to anyone else; it can cause death or harm them. Selling or giving away this medicine is against the law.

To report negative side effects associated with taking ZUBSOLV, please call 1-888-982-7658. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit ww.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information and Medication Guide for ZUBSOLV.